Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Autoimmune disease treatments stories

Nov 11, 2026

Amgen's Sjögren's drug cuts disease activity in trial

Amgen reported positive trial results showing its experimental drug reduced disease activity in patients with Sjögren's syndrome, a chronic autoimmune condition with limited treatment options.

Nov 11, 2026·2 sources
00
Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Nov 5, 2026

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 2026·2 sources
00
Oct 30, 2026

Psoriasis patients face increased cataract risk, study finds

A study published in the Journal of Dermatology found that patients with psoriasis have an increased risk for cataracts and cataract surgery, with risks varying by treatment modality. The research was conducted by Yan-Jie Su from Taipei Veterans General Hospital in Taiwan.

Oct 30, 2026·2 sources
00

FDA approves tildrakizumab for psoriatic arthritis

The FDA cleared Sun Pharma's interleukin-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis in adults, expanding the drug's approved indications.

Oct 30, 2026·3 sources
00

AbbVie raises annual profit forecast on strong immunology drug sales

AbbVie raised its full-year profit forecast after beating third-quarter expectations, driven by strong demand for its newer immunology and neuroscience drugs as the company navigates the Humira patent cliff.

Oct 30, 2026·2 sources
00
Oct 29, 2026

Stem cell transplants show 60% progression-free survival at 10 years for severe systemic sclerosis

An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.

Oct 29, 2026·3 sources
00

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

California biotech Dren Bio secured $350 million in funding to advance its lead blood cancer therapy toward a potential market launch by the end of 2027.

Oct 29, 2026·3 sources
00
Oct 27, 2026

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Artiva Biotherapeutics halted development of its experimental cell therapy for autoimmune conditions following two patient deaths in clinical trials and announced massive workforce reductions.

Oct 27, 2026·4 sources
00
Oct 23, 2026

Three drugs show sustained kidney function benefits in IgA nephropathy trials at 2 years

Atacicept, telitacicept, and sibeprenlimab demonstrated unprecedented benefits in stabilizing kidney function in phase 3 trials for IgA nephropathy, with sustained effects at two years.

Oct 23, 2026·2 sources
00

Bristol Myers patient died after CAR-T treatment, company explains June trial pause

Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.

Oct 23, 2026·5 sources
00

UK approves Johnson & Johnson's oral psoriasis pill for moderate-to-severe plaque psoriasis

Britain's medicines regulator approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy patches.

Oct 23, 2026·2 sources
00
Oct 22, 2026

Rituximab linked to increased inflammatory bowel disease risk in multiple sclerosis patients

A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.

Oct 22, 2026·2 sources
00

Gilead acquires PepStar inflammation drug program for $1.28 billion

Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.

Oct 22, 2026·3 sources
00
Oct 21, 2026

Roivant's brepocitinib succeeds in phase 3 trials for non-infectious uveitis

Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.

Oct 21, 2026·7 sources
00
Oct 20, 2026

ARCTIC trial shows excellent 10-year outcomes with treat-to-target strategy in early rheumatoid arthritis

A new study from the ARCTIC trial demonstrates that patients with early rheumatoid arthritis managed with a treat-to-target strategy achieved favorable long-term outcomes over 10 years. Patients who achieved sustained remission at two years showed higher remission rates and better physical function throughout the decade-long follow-up period.

Oct 20, 2026·2 sources
00
Oct 19, 2026

Mirikizumab achieves clinical remission in pediatric ulcerative colitis phase 3 trial

Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.

Oct 19, 2026·3 sources
00
Oct 16, 2026

Satralizumab approved as first at-home treatment for thyroid eye disease

The FDA has approved satralizumab (Enspryng) as the first self-administered therapy for thyroid eye disease, expanding treatment options beyond the existing intravenous therapies.

Oct 16, 2026·2 sources
00
Oct 9, 2026

TRexBio raises $116.7 million in IPO for autoimmune disease treatments

TRexBio Inc., an early-stage biotech company focused on autoimmune and inflammatory diseases, raised $116.7 million in a US initial public offering that priced at the bottom of its marketed range.

Oct 9, 2026·2 sources
00
Oct 8, 2026

Argenx discontinues late-stage Vyvgart trial in Sjögren's disease

Belgian-Dutch pharma Argenx halted a phase 3 study of efgartigimod (Vyvgart) in Sjögren's disease after the drug failed to outperform placebo, sending shares tumbling over 20%.

Oct 8, 2026·4 sources
00
Oct 5, 2026

International panel updates guidelines for CAR T-cell therapy in autoimmune disease

An international multidisciplinary group of 31 experts coordinated by EBMT, ISCT, and JACIE has released updated consensus recommendations for using CAR T-cell therapy in patients with severe, treatment-refractory autoimmune diseases. The guidelines, originally released in 2024, include recommendations around optimizing safety.

Oct 5, 2026·3 sources
00
Oct 2, 2026

Novartis licenses mRNA autoimmune therapy from Abogen for up to $7.8 billion

Novartis agreed to pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to an early-stage CD19xCD3 T cell engager, with the deal valued at up to $7.8 billion including milestones. The mRNA-based therapy targets autoimmune diseases.

Oct 2, 2026·3 sources
00

Novartis licenses mRNA autoimmune therapy from Abogen for up to $7.8 billion

Novartis will pay $500 million upfront and up to $7.3 billion in milestones to license an mRNA-based autoimmune therapy from China's Abogen Biosciences, marking one of the largest biotech deals involving a Chinese company.

Oct 2, 2026·2 sources
00
Sep 28, 2026

Adicet Bio's off-the-shelf CAR-T therapy shows promise in lupus trial

Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.

Sep 28, 2026·4 sources
00
Sep 23, 2026

Immunovant halts IMVT-1402 cutaneous lupus program after phase 2 trial failure

Immunovant has discontinued development of IMVT-1402 for cutaneous lupus erythematosus after the anti-FcRn antibody failed to meet its primary endpoint in a proof-of-concept study of 57 patients. The company's stock fell 6% following the announcement.

Sep 23, 2026·4 sources
00
Sep 8, 2026

Study finds low rate of liver injury from avacopan amid FDA approval review

A U.S. study published in Arthritis & Rheumatology found that only 0.8% of patients treated with avacopan for ANCA-associated vasculitis developed drug-induced liver injury, with liver enzyme elevations being uncommon. The findings come as the FDA considers revoking approval for the drug following earlier safety concerns.

Sep 8, 2026·1 source
00
Sep 3, 2026

Bristol Myers Squibb halts autoimmune drug trials after deaths and life-threatening side effects

Bristol Myers Squibb paused closely watched autoimmune drug research in early June after reports of life-threatening side effects and deaths, notifying regulators, researchers and patient advocacy groups.

Sep 3, 2026·2 sources
00
Aug 31, 2026

Novartis and Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis has halted development of rap-cel in multiple indications and Bristol Myers voluntarily paused enrollment in autoimmune CAR-T trials after observing safety issues in testing.

Aug 31, 2026·2 sources
00
Aug 12, 2026

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Jul 27, 2026

Argenx to Acquire Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

Belgian-Dutch biotech argenx agreed to acquire Forte Biosciences for $2.2 billion in cash ($77 per share, an 86% premium to its VWAP since July 9), adding FB102, an anti-CD122 antibody in development for vitiligo and celiac disease, to its immunology pipeline.

Jul 27, 2026·4 sources
00
Jul 7, 2026

FDA Approves Vera Therapeutics' TRUTAKNA for IgA Nephropathy Treatment

The U.S. Food and Drug Administration has granted accelerated approval to Vera Therapeutics' drug TRUTAKNA for treating adult patients with primary IgA nephropathy, a potentially life-threatening chronic autoimmune kidney disease. The approval sent Vera's shares up 6.8% in afternoon trading.

Jul 7, 2026·3 sources
00
May 5, 2026

UCB Acquires Maker of Antibody Treatments for Autoimmune Diseases

Belgian pharmaceutical company UCB has announced the acquisition of a company specializing in antibody treatments for autoimmune diseases, expanding its immunology portfolio.

May 5, 2026·1 source
00

Top claims

  • ▪In the NEPTUNUS-1 trial involving 275 patients, monthly treatment with 300 mg of ianalumab led to a 1.3-point greater decrease in ESSDAI score compared with placebo from baseline to week 48
  • ▪In Amgen's late-stage trial of 648 patients with moderate-to-severe Sjögren's disease, a 1,500 mg dose of dazodalibep every four weeks lowered disease activity scores by 5.6 points over 48 weeks, compared to 3.8 points for placebo
  • ▪Both tested dosing regimens of Amgen's dazodalibep met the primary trial endpoint for Sjögren's disease, showing significant therapeutic effects as early as week four of treatment

Subtopics

Clinical trials11Autoimmune disease10Drug development10Drug Policy, Pricing & Approval10Biologic therapies8Pharmaceutical Industry8Drug Approval and Clinical Trials7Immunotherapy5Pharma5Biotech startup4FDA drug approval4Immunology4Venture capital funding4Biotechnology3CAR T-cell therapy3Digestive diseases3Drug safety3Eli Lilly3Observational research3Randomized controlled trial3Biotech innovation2Cancer & Oncology2Cancer immunotherapy2Clinical Trial Design & Evaluation2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories